Page 75 - CIBERDEM2016-ENG

Most relevant scientific articles
• Montane J., de Pablo S., Obach M., Cadavez L., Castano C., Alcarraz-Vizan G. et al. Protein disulfide isomerase ameliorates β-cell dysfunction in pancreatic islets overexpressing human islet amyloid polypeptide. Molecular and Cellular Endocrinology. 2016;420:57-65.
• Parrizas M., Novials A.. Circulating microRnAs as biomarkers for metabolic disease. Best Practice and Research: Clinical Endocrinology and Metabolism. 2016;30(5):591-601.
• Brugnara L., Murillo S., Novials A., Rojo-Martínez G., Soriguer F., Goday A. et al. Low physical activity and its association with diabetes and other cardiovascular risk factors: A nationwide, population-based study. PLoS ONE. 2016;11(8).
• Ceriello A., De Nigris V., Pujadas G., La Sala L., Bonfigli A.R., Testa R. et al. The simultaneous control of hyperglycemia and gLP-1 infusion normalize endothelial function in type 1 diabetes. Diabetes Research and Clinical Practice. 2016;114:64-68.
• La Sala L., Cattaneo M., De Nigris V., Pujadas G., Testa R., Bonfigli A.R. et al. Oscillating glucose induces microRNA-185 and impairs an efficient antioxidant response in human endothelial cells. Cardiovascular Diabetology. 2016;15(1).
Highlights
During 2016, we made advancements in our attempts to formulate new strategies for reversing pancreatic islet dysfunction induced by amyloid deposits. In particular, we demonstrated that the overexpression of the endogenous chaperone PDI enables the recovery of beta-cell function in mice expressing human IAPP. We also continued exploring the role that microRnAs play in the pathophysiology of diabetes, identifying a microRNA (miR-185) involved in the reduction of antioxidant response in human endothelial cells. In clinical studies, we participated in a study of the prevalence of sedentariness in the Spanish population, establishing associations between low physical activity and diabetes, along with other cardiovascular risk factors.
Our research group actively collaborates with other CIBERDEM groups, as well as other groups belonging to other CIBER thematic areas. Of special mention is our participation in an integrated project of excellence funded by the Carlos III Health Institute (ISCIII), which seeks to identify the molecular mechanisms common to both diabetes and neurodegenerative disorders.
Throughout 2016, our group continued work on projects funded by national, regional and European agencies including: the Health Research Fund (FIS) of ISCIII; the Research Groups Support grant (SGR) from the government of Catalonia; and the European Commission for the MEDIgEnE project, which ended
in 2016. Moreover, we continue to collaborate with the grífols company, conducting research on anti- inflammatory strategies for treating diabetes.
In terms of social outreach, an activity that stands out is our talk presented within the framework of the large-scale, social networking event, “Diabetes Experience Day”. Finally, our group participated in the activities organized by the AstraZeneca Chair in Diabetes Innovation at IDIBAPS, with the collaboration
of CIBERDEM, including the presentation of the book, Sketching Diabetes, and the initiative, Living Lab, “Diabetes: fighting against sedentary lifestyles.”
DEM
research groups 75